CDKN2A and neoplasm: Following tumor initiation by KRAS mutation, PanIN lesions progress to invasive PDAC through subsequent inactivation of the tumor suppressor genes TP53, cyclin-dependent kinase inhibitor 2A (CDKN2A), and SMAD family member 4 (SMAD4) [36].